Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CA2223702) THERAPEUTIC FRAGMENTS OF VON WILLEBRAND FACTOR

Office : Canada
Application Number: 2223702 Application Date: 06.06.1996
Publication Number: 2223702 Publication Date: 29.05.1997
Grant Number: Grant Date: 29.07.2008
Publication Kind : C
Prior PCT appl.: Application Number:US1996009013 ; Publication Number: Click to see the data
IPC:
C07K 14/755
C07K 1/113
C07K 1/22
A61K 38/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
755
Factors VIII
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
107
by chemical modification of precursor peptides
113
without change of the primary structure
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
14
Extraction; Separation; Purification
16
by chromatography
22
Affinity chromatography or related techniques based upon selective absorption processes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
CPC:
C07K 14/755
A61K 38/00
Applicants: CENTEON L.L.C.
Inventors: FARB, DAVID L.
HRINDA, MICHAEL E.
LEE, TED C. K.
PRIOR, CHRISTOPHER P.
WEBER, DAVID
Priority Data: 08/487,445 07.06.1995 US
Title: (EN) THERAPEUTIC FRAGMENTS OF VON WILLEBRAND FACTOR
(FR) FRAGMENTS THERAPEUTIQUES DU FACTEUR VON WILLEBRAND
Abstract: front page image
(EN) Processes for preparing aqueous solutions of cysteine--altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.


Also published as:
MXPA/a/1997/009893EP0833659JP2001517197 KR1019990022634AU1996060471WO/1997/018834